- Home
- ATRC vs MNKD Comparison
ATRC vs MNKD Comparison
Compare ATRC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- MNKD
- Stock Information
- Founded
- ATRC 2000
- MNKD 1991
- Country
- ATRC United States
- MNKD United States
- Employees
- ATRC N/A
- MNKD N/A
- Industry
- ATRC Medical/Dental Instruments
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- ATRC Health Care
- MNKD Health Care
- Exchange
- ATRC Nasdaq
- MNKD Nasdaq
- Market Cap
- ATRC 1.6B
- MNKD 1.6B
- IPO Year
- ATRC 2005
- MNKD 2004
- Fundamental
- Price
- ATRC $31.13
- MNKD $4.76
- Analyst Decision
- ATRC Strong Buy
- MNKD Buy
- Analyst Count
- ATRC 10
- MNKD 6
- Target Price
- ATRC $48.50
- MNKD $8.92
- AVG Volume (30 Days)
- ATRC 639.5K
- MNKD 2.0M
- Earning Date
- ATRC 04-30-2025
- MNKD 05-07-2025
- Dividend Yield
- ATRC N/A
- MNKD N/A
- EPS Growth
- ATRC N/A
- MNKD N/A
- EPS
- ATRC N/A
- MNKD 0.10
- Revenue
- ATRC $465,307,000.00
- MNKD $285,504,000.00
- Revenue This Year
- ATRC $14.60
- MNKD $14.66
- Revenue Next Year
- ATRC $12.58
- MNKD $14.27
- P/E Ratio
- ATRC N/A
- MNKD $48.80
- Revenue Growth
- ATRC 16.55
- MNKD 43.50
- 52 Week Low
- ATRC $18.94
- MNKD $3.97
- 52 Week High
- ATRC $43.11
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- ATRC 37.03
- MNKD 31.52
- Support Level
- ATRC $31.02
- MNKD $4.89
- Resistance Level
- ATRC $34.30
- MNKD $5.08
- Average True Range (ATR)
- ATRC 1.75
- MNKD 0.13
- MACD
- ATRC -0.03
- MNKD -0.01
- Stochastic Oscillator
- ATRC 10.33
- MNKD 8.70
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.